Tirzepatide's gastric emptying effect is shown to fade with repeat dosing

A study published in Diabetes, Obesity and Metabolism reports that tirzepatide, the drug later sold as Mounjaro and Zepbound, slows stomach emptying about as much as semaglutide (the active ingredient in Ozempic and Wegovy) when first given, but that this effect largely disappears after about two weeks of continued dosing, according to Eli Lilly researchers led by Shweta Urva ^[1].

The finding came from two lines of work. In mice, single doses of tirzepatide delayed gastric emptying to a similar degree as semaglutide, but after two weeks of repeated dosing, this acute effect was abolished in both drugs. A long-acting GIP analog given alone had no effect on gastric emptying at all, and adding it to a GLP-1 drug did not slow emptying any more than the GLP-1 drug by itself ^[1].

In people, Lilly ran two early-stage studies: a four-week, multiple-ascending-dose study in 35 healthy volunteers comparing tirzepatide with dulaglutide (Trulicity), and a four-week proof-of-concept study in 53 people with type 2 diabetes ^[2]. Researchers tracked gastric emptying indirectly by measuring how quickly acetaminophen appeared in the blood after participants swallowed it — a slower rise signals a slower-emptying stomach. After a first dose above 1.5 mg, peak acetaminophen levels fell by about 50% and the time to reach that peak was delayed by about an hour, indicating a real slowdown in gastric emptying ^[2].

By the fourth weekly dose, that slowdown had essentially vanished in the fixed-dose groups — described in the conference abstract as "complete tachyphylaxis" — matching the pattern seen with dulaglutide ^[2]. In people with type 2 diabetes given dose-escalation schedules such as 5-5-10-10 mg or 5-5-10-15 mg, the slowing effect on gastric emptying did not disappear entirely; some residual delay remained after four weeks, which the researchers linked to the titration schedule itself rather than a persistent drug effect ^[1][2].

Why it matters for patients

Slowed stomach emptying is one of the ways GLP-1 and dual GIP/GLP-1 drugs make people feel full faster, and it is also linked to common early side effects like nausea, bloating, and stomach discomfort. This study suggests that for tirzepatide, as for semaglutide, the gastric-emptying effect is strongest right after starting or increasing a dose and then fades with continued weekly use ^[1][2]. That pattern is consistent with what many patients experience: gastrointestinal side effects tend to be worse early in treatment or right after a dose increase, and often ease over the following weeks.

Because the gastric-emptying effect fades, the researchers note that tirzepatide's larger reductions in blood sugar and body weight, compared with a GLP-1-only drug like dulaglutide in earlier data, likely depend on other mechanisms — such as effects on insulin secretion, appetite, and glucagon — rather than on permanently slowing digestion ^[1]. The sources do not say how this early-phase finding, based on 35 to 53 participants over four weeks, translates into the longer-term tolerability patterns reported once tirzepatide reached wider clinical use; that is not addressed in this study.

What happens next

The data reported here come from a mouse study and two short, early-phase human trials in healthy volunteers and people with type 2 diabetes ^[1][2]. The sources do not include follow-up studies confirming whether this tachyphylaxis pattern holds at the higher maintenance doses now used in marketed tirzepatide products, so that remains not yet established from the material provided.